Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Hematology · Chronic Myeloid Leukemia

Long-Term Success: Survivorship and Stopping Treatment

At a Glance

Some people with chronic myeloid leukemia can try treatment-free remission after several years of tyrosine kinase inhibitor therapy and at least two years of a deep response. Stopping is supervised with frequent PCR blood tests, and treatment is restarted if the response is lost.

Living with Chronic Myeloid Leukemia (CML) today is often a marathon, not a sprint. Because modern medications are so effective, the focus for many patients shifts from “treating a crisis” to “managing a chronic condition” [1]. This involves navigating daily side effects, maintaining strict medication habits, and—for some—the possibility of eventually stopping treatment altogether.

The Reality of Long-Term TKI Therapy

While Tyrosine Kinase Inhibitors (TKIs) are life-saving, they are not always easy to live with. Many patients experience “low-grade” side effects that, while not dangerous, can impact your daily quality of life [2].

  • Persistent Fatigue: This is one of the most common complaints and can be caused by the drug itself or by mild myelosuppression (when the drug lowers your healthy blood counts) [3][4].
  • Digestive Issues: Chronic mild nausea or diarrhea (especially with bosutinib) may require changes to your diet or the timing of your dose [5][6].
  • Muscle and Bone Pain: Some patients experience “bone aches” or sudden muscle cramps in their hands or feet [7][8].
  • Adherence is Key: Consistent dosing improves your response and lowers resistance risk [9][10]. Occasional missed doses do happen; if you miss one, do not double up, and contact your care team for your TKI’s specific missed-dose instructions. Using pill organizers or phone alarms is standard practice for long-term success [11].

In survivorship, don’t forget routine health care: keep up with vaccinations, cardiovascular risk management (especially for those on nilotinib or ponatinib), bone health, and age-appropriate cancer screenings.

The Goal of Treatment-Free Remission (TFR)

For a significant number of patients, an ultimate goal may be Treatment-Free Remission (TFR)—stopping your medication under strict medical supervision while staying in a deep response [12]. This is not a “medication holiday” you take on your own; it is a clinical process with specific safety rules [13]. Remaining on a well-tolerated TKI is also a fully successful goal.

Who is eligible to try TFR?

While guidelines vary slightly between organizations like the NCCN and ELN, the general requirements include:

  • Duration of Therapy: Usually at least 3 to 5 years of consistent TKI treatment [14][12].
  • Deep Molecular Response (DMR): You must have achieved and maintained a very low leukemia level (typically MR4 or MR4.5) for at least 2 consecutive years [14][15].
  • Stable History: TFR is most successful for patients who are in their first “chronic phase” and have never shown resistance to their medication [12][16]. You also need access to a standardized PCR laboratory to comply with the frequent monitoring.

What happens if you stop?

About 40% to 50% of carefully selected eligible people who meet these criteria can stay off medication long-term [17][18].

  • The Relapse Window: Most molecular relapses happen early—about 82% occur within the first 6 months of stopping, though late relapses can occur [19]. This is why you will need blood tests every single month during this period, followed by every 2-3 months [12][13].
  • Restarting is Effective: Loss of MMR is generally the trigger to restart your medication. The good news is that most patients regain their MMR quickly once they restart treatment, though returning to prior DMR levels can vary [20][21].
  • “TKI Withdrawal Syndrome”: Surprisingly, about 25% to 30% of patients experience new or worsening muscle and joint pain shortly after stopping their TKI; this is usually temporary but can be distressing if you aren’t expecting it [22].

Managing “Scanxiety” and the Mental Load

The constant monitoring of your BCR::ABL1 levels can lead to significant psychological stress, often called “PCR anxiety” or “scanxiety” [22][23].

  • Understanding the Numbers: Knowing that a tiny fluctuation is normal—and doesn’t mean your cancer is returning—can help lower anxiety [24].
  • Preparation: Reviewing your trend lines with your doctor can provide a sense of control [25].
  • Support Systems: Many patients find that connecting with CML-specific support groups or oncology counselors helps them process the unique burden of living with a “controllable” cancer. Social workers can also assist with medication co-pay assistance and financial toxicity [11][26].

CML is now a journey of decades, and your relationship with your care team will evolve as you move from your initial diagnosis toward long-term stability or even remission [2].

Common questions in this guide

What is treatment-free remission in CML?
Treatment-free remission means stopping a tyrosine kinase inhibitor while remaining in remission under close medical supervision. It requires a sustained deep molecular response and frequent blood testing. Staying on a well-tolerated TKI is also a successful treatment goal.
Who may be able to stop CML treatment?
Eligibility usually includes at least 3 to 5 years of TKI therapy and a very deep response, such as MR4 or MR4.5, maintained for at least 2 years. People are more likely to succeed if they are in their first chronic phase, have not had treatment resistance, and can receive reliable PCR monitoring.
How often are blood tests needed after stopping a CML medication?
Blood tests are generally needed every month during the first 6 months, when molecular relapse is most likely. Testing is then commonly spaced to every 2 to 3 months, according to the monitoring plan from your care team.
What happens if CML returns after I stop my TKI?
A rising leukemia level or loss of a major molecular response usually leads the care team to restart treatment. Most patients regain their major molecular response quickly after restarting a TKI, although returning to the deepest previous response can take different amounts of time.
What long-term side effects can CML TKIs cause?
Long-term TKI treatment may be associated with fatigue, mild nausea or diarrhea, muscle cramps, and bone or joint pain. Your care team can look for other causes, adjust supportive care, or discuss medication changes; do not stop or alter your TKI on your own.
What is TKI withdrawal syndrome?
TKI withdrawal syndrome is new or worsening muscle or joint pain that can occur after a person stops a tyrosine kinase inhibitor. It is often temporary, but you should tell your care team about symptoms so they can help manage them.
How can I manage anxiety while waiting for CML PCR results?
Reviewing your BCR::ABL1 trend with your clinician can make small fluctuations easier to understand and may reduce worry. CML support groups, oncology counselors, and social workers can also help with emotional stress, practical concerns, and medication costs.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my BCR::ABL1 history, am I currently a candidate for a Treatment-Free Remission (TFR) trial, or what milestones do I still need to reach?
  2. 2.If we decide to attempt TFR, what is the exact schedule for my blood tests during the first year, and what 'number' will trigger us to restart my medication?
  3. 3.How do we distinguish my chronic fatigue from other possible causes like anemia or thyroid issues?
  4. 4.Are there specific lifestyle changes or supportive medications you recommend to manage my daily muscle cramps or digestive issues?
  5. 5.If I have to restart my TKI after a molecular relapse, what is the likelihood that I will regain my previous deep response?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (26)
  1. 1

    Chronic Myeloid Leukemia: A Review.

    Jabbour E, Kantarjian H

    JAMA 2025; (333(18)):1618-1629 doi:10.1001/jama.2025.0220.

    PMID: 40094679
  2. 2

    Optimizing patient selection for treatment-free remission.

    Rausch CR, Paul S

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2020; (26(5)):1220-1224 doi:10.1177/1078155220925167.

    PMID: 32437235
  3. 3

    The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.

    Shoukier M, Borthakur G, Jabbour E, et al.

    Haematologica 2021; (106(11)):2853-2858 doi:10.3324/haematol.2020.260125.

    PMID: 33054123
  4. 4

    European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

    Steegmann JL, Baccarani M, Breccia M, et al.

    Leukemia 2016; (30(8)):1648-71 doi:10.1038/leu.2016.104.

    PMID: 27121688
  5. 5

    Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.

    Hochhaus A, Gambacorti-Passerini C, Abboud C, et al.

    Leukemia 2020; (34(8)):2125-2137 doi:10.1038/s41375-020-0915-9.

    PMID: 32572189
  6. 6

    Practical recommendation for rash and diarrhea management in Indian patients treated with tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.

    Parikh P, Prabhash K, Naik R, et al.

    Indian journal of cancer 2016; (53(1)):87-91 doi:10.4103/0019-509X.180863.

    PMID: 27146751
  7. 7

    Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?

    Iurlo A, Orsi E, Cattaneo D, et al.

    Oncotarget 2015; (6(32)):33944-51 doi:10.18632/oncotarget.5580.

    PMID: 26376678
  8. 8

    Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?

    Osorio S, Escudero-Vilaplana V, Gómez-Centurión I, et al.

    Annals of hematology 2018; (97(11)):2089-2098 doi:10.1007/s00277-018-3413-7.

    PMID: 29955943
  9. 9

    Late Emergence of an Imatinib-Resistant ABL1 Kinase Domain Mutation in a Patient with Chronic Myeloid Leukemia.

    Crampe M, Andrews C, Fortune A, Langabeer SE

    Case reports in hematology 2017; (2017()):3548936 doi:10.1155/2017/3548936.

    PMID: 29375916
  10. 10

    Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors.

    Rosentreter J, Alt J, Fried M, et al.

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2021; (27(5)):1147-1158 doi:10.1177/1078155220946381.

    PMID: 32746691
  11. 11

    Living with chronic myelogenous leukemia in rural communities: Exploring factors related to tyrosine kinase inhibitors adherence with a mixed methods approach.

    Sheng J, Heiney SP, Wickersham KE, et al.

    The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association 2025; (41(2)):e70028 doi:10.1111/jrh.70028.

    PMID: 40285411
  12. 12

    Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel.

    Pavlovsky C, Abello Polo V, Pagnano K, et al.

    Blood advances 2021; (5(23)):4855-4863 doi:10.1182/bloodadvances.2020003235.

    PMID: 34438444
  13. 13

    Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?

    Atallah E, Schiffer CA

    Haematologica 2020; (105(12)):2738-2745 doi:10.3324/haematol.2019.242891.

    PMID: 33054106
  14. 14

    [Chronic myeloid leukemia: state-of-the-art management].

    Takahashi N

    [Rinsho ketsueki] The Japanese journal of clinical hematology 2018; (59(6)):747-754 doi:10.11406/rinketsu.59.747.

    PMID: 29973455
  15. 15

    Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.

    Ross DM, Masszi T, Gómez Casares MT, et al.

    Journal of cancer research and clinical oncology 2018; (144(5)):945-954 doi:10.1007/s00432-018-2604-x.

    PMID: 29468438
  16. 16

    Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.

    Mahon FX, Boquimpani C, Kim DW, et al.

    Annals of internal medicine 2018; (168(7)):461-470 doi:10.7326/M17-1094.

    PMID: 29459949
  17. 17

    Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis.

    Chen KK, Du TF, Xiong PS, et al.

    Frontiers in oncology 2019; (9()):372 doi:10.3389/fonc.2019.00372.

    PMID: 31139566
  18. 18

    Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.

    Ross DM, Pagani IS, Shanmuganathan N, et al.

    Leukemia 2018; (32(12)):2572-2579 doi:10.1038/s41375-018-0264-0.

    PMID: 30315232
  19. 19

    Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.

    Saussele S, Richter J, Guilhot J, et al.

    The Lancet. Oncology 2018; (19(6)):747-757 doi:10.1016/S1470-2045(18)30192-X.

    PMID: 29735299
  20. 20

    Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.

    Hochhaus A, Masszi T, Giles FJ, et al.

    Leukemia 2017; (31(7)):1525-1531 doi:10.1038/leu.2017.63.

    PMID: 28218239
  21. 21

    Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update.

    Hughes TP, Clementino NCD, Fominykh M, et al.

    Leukemia 2021; (35(6)):1631-1642 doi:10.1038/s41375-021-01260-y.

    PMID: 33980976
  22. 22

    Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.

    Bhalla S, Tremblay D, Mascarenhas J

    Clinical lymphoma, myeloma & leukemia 2016; (16(9)):488-494 doi:10.1016/j.clml.2016.06.012.

    PMID: 27406834
  23. 23

    Minimal Residual Disease Eradication in CML: Does It Really Matter?

    Tantravahi SK, Guthula RS, O'Hare T, Deininger MW

    Current hematologic malignancy reports 2017; (12(5)):495-505 doi:10.1007/s11899-017-0409-7.

    PMID: 28852963
  24. 24

    Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study.

    White HE, Salmon M, Albano F, et al.

    Leukemia 2022; (36(7)):1834-1842 doi:10.1038/s41375-022-01607-z.

    PMID: 35614319
  25. 25

    BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

    Cuellar S, Vozniak M, Rhodes J, et al.

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2018; (24(6)):433-452 doi:10.1177/1078155217710553.

    PMID: 28580869
  26. 26

    First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.

    Saglio G, Jabbour E

    Leukemia & lymphoma 2018; (59(7)):1523-1538 doi:10.1080/10428194.2017.1379074.

    PMID: 28972424

This page is for informational purposes only and does not constitute medical advice about CML treatment or treatment-free remission. Discuss eligibility, monitoring, side effects, and any medication changes with your hematology or oncology team.

Get notified when new evidence is published on Philadelphia-positive myelogenous leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.